At a Glance
- Company: Argenica Therapeutics Ltd (ASX: AGN)
- Location: Australia (HQ); Europe (EMA approval pathway)
- Headline: Full Product-Specific Paediatric Waiver granted
- Focus area: ARG-007 neuroprotective therapy for acute ischaemic stroke
- Next steps: Proceed to phase 2b/3 RESCUE pivotal trials
What happened?
Argenica Therapeutics secured a full Product-Specific Paediatric Waiver from the European Medicines Agency (EMA) for ARG-007 on 3 February 2026. The decision eliminates the need for paediatric clinical trials, confirming the EMA will assess ARG-007 for adult acute ischaemic stroke (AIS) based solely on adult data.
Why does it matter?
Acute ischaemic stroke predominantly affects adults, with paediatric cases being rare; mandating child trials would add years of delay and significant costs without clinical benefit. The waiver streamlines the Marketing Authorisation Application (MAA), reduces regulatory risk and enhances ARG-007’s appeal to potential pharma partners.
Who’s behind it?
Argenica develops ARG-007, a neuroprotective peptide designed to limit brain tissue death post-stroke by crossing the blood-brain barrier rapidly. Led by Managing Director Dr Liz Dallimore, the company advances the asset toward pivotal trials.
How was it achieved?
The EMA’s Paediatric Committee (PDCO) recommended the waiver, granted because paediatric studies are “highly impracticable” for adult-focused AIS indications, aligning with EU regulations. This supports progression to the phase 2b/3 RESCUE study design.
What’s next?
Argenica advances global regulatory strategy, prioritising adult AIS trials with EMA alignment; the de-risked pathway supports partnering discussions.
What are people saying
Dr Liz Dallimore: “Key milestone… provides clarity and certainty… viewed favourably by potential pharmaceutical partners.”